SPARC

SPARC has undergone a strategic reset, narrowing its therapeutic focus to oncology and immunology. This involved prioritizing two promising programs, MUC1 ADC in solid tumors (SBO-154) and a topical intervention in Alopecia Areata (SCD-153), which were nearing clinical entry. The company aims to reduce clinical risk and explore alternative structures like NewCos for development, as evidenced by the collaboration with Tiller Therapeutics for SMDCs. This strategic shift is intended to optimize cost structure and resource allocation for aggressive portfolio build-out.

The company has aggressively optimized its cost structure, projecting a reduction in operational spend from $31 million last year to $29 million this year. This includes achieving approximately $10 million in annual fixed cost savings. Headcount has been reduced from over 400 to around 250, and the US footprint is being reduced, with a shift towards increasing the India component of clinical development efforts, leveraging lower costs and an improving research environment.

SCD-153, a novel topical itaconate analogue, is currently in a Phase 1B clinical trial for alopecia areata. Enrollment in all cohorts is targeted for completion by Q3 2026, with interim readout expected in Q4 2026. The study protocol was amended to use a foam formulation from cohort 2 onwards, and the DSMB has approved progression to the second cohort. SPARC is also exploring SCD-153 for vitiligo, based on preclinical in-vitro studies showing inhibition of key chemokines and cytokines involved in its pathogenesis, with plans for clinical study initiation after animal model results.

SBO-154, an anti-MUC1 antibody drug conjugate (ADC) with MMAE payload, is undergoing a Phase 1 dose escalation study in solid tumors across the US, Australia, and India. The first two dose cohorts have completed enrollment without unexpected safety findings, and the third cohort has been initiated. The company expects to complete dosing to the highest dose cohort (2.4 mg/kg) by Q3 2026, with potential for early clinical proof of concept by H2 2027. The unique binding epitope targeting alpha-beta junctions aims to reduce sink effect and improve tumor targeting.

SPARC received a favorable ruling from the district court regarding its Pediatric Rare Diseases Voucher (PRV), expecting to receive a tradeable voucher that could lead to a significant encashment, with the appeal window closing by end of January. For PDP-716 (Brimonidine), while the API vendor's regulatory status has changed, the finished product manufacturing site still has compliance issues. SPARC is working with Ocuvex Therapeutics to qualify third-party sites to address these challenges and clear the regulatory gate.

The company is advancing SCO-155, a small-molecule drug conjugate, through a NewCo structure (Tiller Therapeutics) formed with UCSF collaborators. Tiller has secured pre-seed capital and is raising external seed capital for its early-stage clinical program. SPARC's preclinical pipeline is focused on three themes: targeted delivery to tumors (including ADCs, SMDCs, and antibody-coated nanoparticles), synthetic lethality (targeting DNA repair pathways), and dermatology autoimmune disorders (seeking safer topical alternatives).